SIC 2835 – In Vitro and In Vivo Diagnostic Substances
Valuation | |
---|---|
Market Cap ($M) | 6,896.81 |
Enterprise Value ($M) | 7,112.99 |
Book Value ($M) | 1,088.01 |
Book Value / Share | 15.86 |
Price / Book | 6.34 |
NCAV ($M) | 434.30 |
NCAV / Share | 6.33 |
Price / NCAV | 15.88 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.14 |
Return on Assets (ROA) | 0.17 |
Return on Equity (ROE) | 0.33 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 5.23 |
Current Ratio | 5.52 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 1,326.63 |
Assets | 1,980.34 |
Liabilities | 892.33 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 1,533.91 |
Operating Income | 448.56 |
Net Income | 312.44 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 544.75 |
Cash from Investing | -226.01 |
Cash from Financing | -118.54 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Janus Henderson Group Plc | 8.90 | 72.73 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
104,800 | 342,785 | 30.57 | |
171,021 | 634,637 | 26.95 | |
183,571 | 494,691 | 37.11 | |
201,554 | 601,897 | 33.49 | |
(click for more detail) |
Similar Companies | |
---|---|
KROS – Keros Therapeutics, Inc. | KYMR – Kymera Therapeutics, Inc. |
LGND – Ligand Pharmaceuticals Incorporated | LRMR – Larimar Therapeutics, Inc. |
LXEO – Lexeo Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io